Global Cardiac Biomarkers Testing Market
Global Cardiac Biomarkers Testing Market

Cardiac Biomarkers Testing Comprehensive Study by Type (Myocardial Muscle Creatine Kinase (CK-MB), Troponins (T and I), Myoglobin, Brain Natriuretic Peptide (BNPs) or NT-proBNP, Ischemia-modified Albumin (IMA), Others), Application (Myocardial Infarction, Congestive Heart Failure, Acute Coronary Syndrome, Atherosclerosis, Others), Product (Instruments, Chemiluminescence, Immunofluorescence, ELISA, Immunochromatography, Reagents and Kits), Location of Testing (Point of Care Testing, Laboratory Testing) Players and Region - Global Market Outlook to 2026

Cardiac Biomarkers Testing Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

Jan 2021 Edition 226 Pages 210 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Cardiac Biomarkers Testing Market Scope
Cardiac biomarkers are substances released into the blood when the heart is damaged or stressed. Cardiac biomarker testing is commonly used for and diagnosis and risk stratification in patients presenting with symptoms of AMI. These biomarkers are used to diagnose heart functioning, risk stratifications, and cardiac diseases in patients. A biomarker is a quantifiable and measurable biological parameter that includes an enzyme, hormones, and proteins, all associated with heart function, failure, or damage. Point of Care Cardiac Biomarker tests includes Troponin I, CK-MB, BNP, Pro-BNP, D-Dimer, and Myoglobin. CLIA-Waived and moderately complex platforms use small blood volumes of whole or venous samples. Time to results in minutes.

The Cardiac Biomarkers Testing market study is segmented by Type (Myocardial Muscle Creatine Kinase (CK-MB), Troponins (T and I), Myoglobin, Brain Natriuretic Peptide (BNPs) or NT-proBNP, Ischemia-modified Albumin (IMA) and Others), by Application (Myocardial Infarction, Congestive Heart Failure, Acute Coronary Syndrome, Atherosclerosis and Others) and major geographies with country level break-up.

The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Research Analyst at AMA estimates that Global Players will contribute to the maximum growth of Global Cardiac Biomarkers Testing market throughout the predicted period.

Abbott Laboratories (United States), Becton, Dickinson and Company (United States), BioMerieux SA (France), Bio-Rad Laboratories, Inc. (United States), Danaher Corporation (United States), Roche Holding AG (Switzerland), Siemens AG (Germany), Thermo Fisher Scientific, Inc. (United States), PerkinElmer Inc. (United kingdom) and Tosoh Corporation (Japan) are some of the key players that are part of study coverage.

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a
preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from total available market.

Segmentation Overview
AdvanceMarketAnalytics has segmented the market of Global Cardiac Biomarkers Testing market by Type, Application and Region.

On the basis of geography, the market of Cardiac Biomarkers Testing has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).




Market Trend
  • Surging Preference for Point of Care (POC) Cardiac Testing Kits
  • Increase in R&D Activities related to Cardiac Biomarkers

Market Drivers
  • Increasing Prevalence of Cardiovascular Diseases
  • Rising Technological Advancements using Cardiac Biomarkers Combinations

Opportunities
  • Increase in Awareness about the Importance of Early Diagnosis
  • Advancements in Healthcare Facilities

Restraints
  • Confirmation in Result
  • Complex Process

Challenges
  • Streight Government Regulation


Key Target Audience
Cardiac Biomarkers Testing Providers, Research Organizations and Consulting Companies, Potential Technology Investors, Regulatory & Government Bodies, Downstream Vendors, End Users and Others

Customization available in this Study:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase
Report Objectives / Segmentation Covered
By Type
  • Myocardial Muscle Creatine Kinase (CK-MB)
  • Troponins (T and I)
  • Myoglobin
  • Brain Natriuretic Peptide (BNPs) or NT-proBNP
  • Ischemia-modified Albumin (IMA)
  • Others
By Application
  • Myocardial Infarction
  • Congestive Heart Failure
  • Acute Coronary Syndrome
  • Atherosclerosis
  • Others
By Product
  • Instruments
  • Chemiluminescence
  • Immunofluorescence
  • ELISA
  • Immunochromatography
  • Reagents and Kits

By Location of Testing
  • Point of Care Testing
  • Laboratory Testing

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Prevalence of Cardiovascular Diseases
      • 3.2.2. Rising Technological Advancements using Cardiac Biomarkers Combinations
    • 3.3. Market Challenges
      • 3.3.1. Streight Government Regulation
    • 3.4. Market Trends
      • 3.4.1. Surging Preference for Point of Care (POC) Cardiac Testing Kits
      • 3.4.2. Increase in R&D Activities related to Cardiac Biomarkers
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Cardiac Biomarkers Testing, by Type, Application, Product, Location of Testing and Region (value and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Cardiac Biomarkers Testing (Value)
      • 5.2.1. Global Cardiac Biomarkers Testing by: Type (Value)
        • 5.2.1.1. Myocardial Muscle Creatine Kinase (CK-MB)
        • 5.2.1.2. Troponins (T and I)
        • 5.2.1.3. Myoglobin
        • 5.2.1.4. Brain Natriuretic Peptide (BNPs) or NT-proBNP
        • 5.2.1.5. Ischemia-modified Albumin (IMA)
        • 5.2.1.6. Others
      • 5.2.2. Global Cardiac Biomarkers Testing by: Application (Value)
        • 5.2.2.1. Myocardial Infarction
        • 5.2.2.2. Congestive Heart Failure
        • 5.2.2.3. Acute Coronary Syndrome
        • 5.2.2.4. Atherosclerosis
        • 5.2.2.5. Others
      • 5.2.3. Global Cardiac Biomarkers Testing by: Product (Value)
        • 5.2.3.1. Instruments
        • 5.2.3.2. Chemiluminescence
        • 5.2.3.3. Immunofluorescence
        • 5.2.3.4. ELISA
        • 5.2.3.5. Immunochromatography
        • 5.2.3.6. Reagents and Kits
      • 5.2.4. Global Cardiac Biomarkers Testing by: Location of Testing (Value)
        • 5.2.4.1. Point of Care Testing
        • 5.2.4.2. Laboratory Testing
      • 5.2.5. Global Cardiac Biomarkers Testing Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Cardiac Biomarkers Testing (Price)
      • 5.3.1. Global Cardiac Biomarkers Testing by: Type (Price)
  • 6. Cardiac Biomarkers Testing: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Abbott Laboratories (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Becton, Dickinson and Company (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. BioMerieux SA (France)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Bio-Rad Laboratories, Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Danaher Corporation (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Roche Holding AG (Switzerland)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Siemens AG (Germany)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Thermo Fisher Scientific, Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. PerkinElmer Inc. (United kingdom)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Tosoh Corporation (Japan)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Cardiac Biomarkers Testing Sale, by Type, Application, Product, Location of Testing and Region (value and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Cardiac Biomarkers Testing (Value)
      • 7.2.1. Global Cardiac Biomarkers Testing by: Type (Value)
        • 7.2.1.1. Myocardial Muscle Creatine Kinase (CK-MB)
        • 7.2.1.2. Troponins (T and I)
        • 7.2.1.3. Myoglobin
        • 7.2.1.4. Brain Natriuretic Peptide (BNPs) or NT-proBNP
        • 7.2.1.5. Ischemia-modified Albumin (IMA)
        • 7.2.1.6. Others
      • 7.2.2. Global Cardiac Biomarkers Testing by: Application (Value)
        • 7.2.2.1. Myocardial Infarction
        • 7.2.2.2. Congestive Heart Failure
        • 7.2.2.3. Acute Coronary Syndrome
        • 7.2.2.4. Atherosclerosis
        • 7.2.2.5. Others
      • 7.2.3. Global Cardiac Biomarkers Testing by: Product (Value)
        • 7.2.3.1. Instruments
        • 7.2.3.2. Chemiluminescence
        • 7.2.3.3. Immunofluorescence
        • 7.2.3.4. ELISA
        • 7.2.3.5. Immunochromatography
        • 7.2.3.6. Reagents and Kits
      • 7.2.4. Global Cardiac Biomarkers Testing by: Location of Testing (Value)
        • 7.2.4.1. Point of Care Testing
        • 7.2.4.2. Laboratory Testing
      • 7.2.5. Global Cardiac Biomarkers Testing Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Cardiac Biomarkers Testing (Price)
      • 7.3.1. Global Cardiac Biomarkers Testing by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Cardiac Biomarkers Testing: by Type(USD Million)
  • Table 2. Cardiac Biomarkers Testing Myocardial Muscle Creatine Kinase (CK-MB) , by Region USD Million (2015-2020)
  • Table 3. Cardiac Biomarkers Testing Troponins (T and I) , by Region USD Million (2015-2020)
  • Table 4. Cardiac Biomarkers Testing Myoglobin , by Region USD Million (2015-2020)
  • Table 5. Cardiac Biomarkers Testing Brain Natriuretic Peptide (BNPs) or NT-proBNP , by Region USD Million (2015-2020)
  • Table 6. Cardiac Biomarkers Testing Ischemia-modified Albumin (IMA) , by Region USD Million (2015-2020)
  • Table 7. Cardiac Biomarkers Testing Others , by Region USD Million (2015-2020)
  • Table 8. Cardiac Biomarkers Testing: by Application(USD Million)
  • Table 9. Cardiac Biomarkers Testing Myocardial Infarction , by Region USD Million (2015-2020)
  • Table 10. Cardiac Biomarkers Testing Congestive Heart Failure , by Region USD Million (2015-2020)
  • Table 11. Cardiac Biomarkers Testing Acute Coronary Syndrome , by Region USD Million (2015-2020)
  • Table 12. Cardiac Biomarkers Testing Atherosclerosis , by Region USD Million (2015-2020)
  • Table 13. Cardiac Biomarkers Testing Others , by Region USD Million (2015-2020)
  • Table 14. Cardiac Biomarkers Testing: by Product(USD Million)
  • Table 15. Cardiac Biomarkers Testing Instruments , by Region USD Million (2015-2020)
  • Table 16. Cardiac Biomarkers Testing Chemiluminescence , by Region USD Million (2015-2020)
  • Table 17. Cardiac Biomarkers Testing Immunofluorescence , by Region USD Million (2015-2020)
  • Table 18. Cardiac Biomarkers Testing ELISA , by Region USD Million (2015-2020)
  • Table 19. Cardiac Biomarkers Testing Immunochromatography , by Region USD Million (2015-2020)
  • Table 20. Cardiac Biomarkers Testing Reagents and Kits , by Region USD Million (2015-2020)
  • Table 21. Cardiac Biomarkers Testing: by Location of Testing(USD Million)
  • Table 22. Cardiac Biomarkers Testing Point of Care Testing , by Region USD Million (2015-2020)
  • Table 23. Cardiac Biomarkers Testing Laboratory Testing , by Region USD Million (2015-2020)
  • Table 24. South America Cardiac Biomarkers Testing, by Country USD Million (2015-2020)
  • Table 25. South America Cardiac Biomarkers Testing, by Type USD Million (2015-2020)
  • Table 26. South America Cardiac Biomarkers Testing, by Application USD Million (2015-2020)
  • Table 27. South America Cardiac Biomarkers Testing, by Product USD Million (2015-2020)
  • Table 28. South America Cardiac Biomarkers Testing, by Location of Testing USD Million (2015-2020)
  • Table 29. Brazil Cardiac Biomarkers Testing, by Type USD Million (2015-2020)
  • Table 30. Brazil Cardiac Biomarkers Testing, by Application USD Million (2015-2020)
  • Table 31. Brazil Cardiac Biomarkers Testing, by Product USD Million (2015-2020)
  • Table 32. Brazil Cardiac Biomarkers Testing, by Location of Testing USD Million (2015-2020)
  • Table 33. Argentina Cardiac Biomarkers Testing, by Type USD Million (2015-2020)
  • Table 34. Argentina Cardiac Biomarkers Testing, by Application USD Million (2015-2020)
  • Table 35. Argentina Cardiac Biomarkers Testing, by Product USD Million (2015-2020)
  • Table 36. Argentina Cardiac Biomarkers Testing, by Location of Testing USD Million (2015-2020)
  • Table 37. Rest of South America Cardiac Biomarkers Testing, by Type USD Million (2015-2020)
  • Table 38. Rest of South America Cardiac Biomarkers Testing, by Application USD Million (2015-2020)
  • Table 39. Rest of South America Cardiac Biomarkers Testing, by Product USD Million (2015-2020)
  • Table 40. Rest of South America Cardiac Biomarkers Testing, by Location of Testing USD Million (2015-2020)
  • Table 41. Asia Pacific Cardiac Biomarkers Testing, by Country USD Million (2015-2020)
  • Table 42. Asia Pacific Cardiac Biomarkers Testing, by Type USD Million (2015-2020)
  • Table 43. Asia Pacific Cardiac Biomarkers Testing, by Application USD Million (2015-2020)
  • Table 44. Asia Pacific Cardiac Biomarkers Testing, by Product USD Million (2015-2020)
  • Table 45. Asia Pacific Cardiac Biomarkers Testing, by Location of Testing USD Million (2015-2020)
  • Table 46. China Cardiac Biomarkers Testing, by Type USD Million (2015-2020)
  • Table 47. China Cardiac Biomarkers Testing, by Application USD Million (2015-2020)
  • Table 48. China Cardiac Biomarkers Testing, by Product USD Million (2015-2020)
  • Table 49. China Cardiac Biomarkers Testing, by Location of Testing USD Million (2015-2020)
  • Table 50. Japan Cardiac Biomarkers Testing, by Type USD Million (2015-2020)
  • Table 51. Japan Cardiac Biomarkers Testing, by Application USD Million (2015-2020)
  • Table 52. Japan Cardiac Biomarkers Testing, by Product USD Million (2015-2020)
  • Table 53. Japan Cardiac Biomarkers Testing, by Location of Testing USD Million (2015-2020)
  • Table 54. India Cardiac Biomarkers Testing, by Type USD Million (2015-2020)
  • Table 55. India Cardiac Biomarkers Testing, by Application USD Million (2015-2020)
  • Table 56. India Cardiac Biomarkers Testing, by Product USD Million (2015-2020)
  • Table 57. India Cardiac Biomarkers Testing, by Location of Testing USD Million (2015-2020)
  • Table 58. South Korea Cardiac Biomarkers Testing, by Type USD Million (2015-2020)
  • Table 59. South Korea Cardiac Biomarkers Testing, by Application USD Million (2015-2020)
  • Table 60. South Korea Cardiac Biomarkers Testing, by Product USD Million (2015-2020)
  • Table 61. South Korea Cardiac Biomarkers Testing, by Location of Testing USD Million (2015-2020)
  • Table 62. Taiwan Cardiac Biomarkers Testing, by Type USD Million (2015-2020)
  • Table 63. Taiwan Cardiac Biomarkers Testing, by Application USD Million (2015-2020)
  • Table 64. Taiwan Cardiac Biomarkers Testing, by Product USD Million (2015-2020)
  • Table 65. Taiwan Cardiac Biomarkers Testing, by Location of Testing USD Million (2015-2020)
  • Table 66. Australia Cardiac Biomarkers Testing, by Type USD Million (2015-2020)
  • Table 67. Australia Cardiac Biomarkers Testing, by Application USD Million (2015-2020)
  • Table 68. Australia Cardiac Biomarkers Testing, by Product USD Million (2015-2020)
  • Table 69. Australia Cardiac Biomarkers Testing, by Location of Testing USD Million (2015-2020)
  • Table 70. Rest of Asia-Pacific Cardiac Biomarkers Testing, by Type USD Million (2015-2020)
  • Table 71. Rest of Asia-Pacific Cardiac Biomarkers Testing, by Application USD Million (2015-2020)
  • Table 72. Rest of Asia-Pacific Cardiac Biomarkers Testing, by Product USD Million (2015-2020)
  • Table 73. Rest of Asia-Pacific Cardiac Biomarkers Testing, by Location of Testing USD Million (2015-2020)
  • Table 74. Europe Cardiac Biomarkers Testing, by Country USD Million (2015-2020)
  • Table 75. Europe Cardiac Biomarkers Testing, by Type USD Million (2015-2020)
  • Table 76. Europe Cardiac Biomarkers Testing, by Application USD Million (2015-2020)
  • Table 77. Europe Cardiac Biomarkers Testing, by Product USD Million (2015-2020)
  • Table 78. Europe Cardiac Biomarkers Testing, by Location of Testing USD Million (2015-2020)
  • Table 79. Germany Cardiac Biomarkers Testing, by Type USD Million (2015-2020)
  • Table 80. Germany Cardiac Biomarkers Testing, by Application USD Million (2015-2020)
  • Table 81. Germany Cardiac Biomarkers Testing, by Product USD Million (2015-2020)
  • Table 82. Germany Cardiac Biomarkers Testing, by Location of Testing USD Million (2015-2020)
  • Table 83. France Cardiac Biomarkers Testing, by Type USD Million (2015-2020)
  • Table 84. France Cardiac Biomarkers Testing, by Application USD Million (2015-2020)
  • Table 85. France Cardiac Biomarkers Testing, by Product USD Million (2015-2020)
  • Table 86. France Cardiac Biomarkers Testing, by Location of Testing USD Million (2015-2020)
  • Table 87. Italy Cardiac Biomarkers Testing, by Type USD Million (2015-2020)
  • Table 88. Italy Cardiac Biomarkers Testing, by Application USD Million (2015-2020)
  • Table 89. Italy Cardiac Biomarkers Testing, by Product USD Million (2015-2020)
  • Table 90. Italy Cardiac Biomarkers Testing, by Location of Testing USD Million (2015-2020)
  • Table 91. United Kingdom Cardiac Biomarkers Testing, by Type USD Million (2015-2020)
  • Table 92. United Kingdom Cardiac Biomarkers Testing, by Application USD Million (2015-2020)
  • Table 93. United Kingdom Cardiac Biomarkers Testing, by Product USD Million (2015-2020)
  • Table 94. United Kingdom Cardiac Biomarkers Testing, by Location of Testing USD Million (2015-2020)
  • Table 95. Netherlands Cardiac Biomarkers Testing, by Type USD Million (2015-2020)
  • Table 96. Netherlands Cardiac Biomarkers Testing, by Application USD Million (2015-2020)
  • Table 97. Netherlands Cardiac Biomarkers Testing, by Product USD Million (2015-2020)
  • Table 98. Netherlands Cardiac Biomarkers Testing, by Location of Testing USD Million (2015-2020)
  • Table 99. Rest of Europe Cardiac Biomarkers Testing, by Type USD Million (2015-2020)
  • Table 100. Rest of Europe Cardiac Biomarkers Testing, by Application USD Million (2015-2020)
  • Table 101. Rest of Europe Cardiac Biomarkers Testing, by Product USD Million (2015-2020)
  • Table 102. Rest of Europe Cardiac Biomarkers Testing, by Location of Testing USD Million (2015-2020)
  • Table 103. MEA Cardiac Biomarkers Testing, by Country USD Million (2015-2020)
  • Table 104. MEA Cardiac Biomarkers Testing, by Type USD Million (2015-2020)
  • Table 105. MEA Cardiac Biomarkers Testing, by Application USD Million (2015-2020)
  • Table 106. MEA Cardiac Biomarkers Testing, by Product USD Million (2015-2020)
  • Table 107. MEA Cardiac Biomarkers Testing, by Location of Testing USD Million (2015-2020)
  • Table 108. Middle East Cardiac Biomarkers Testing, by Type USD Million (2015-2020)
  • Table 109. Middle East Cardiac Biomarkers Testing, by Application USD Million (2015-2020)
  • Table 110. Middle East Cardiac Biomarkers Testing, by Product USD Million (2015-2020)
  • Table 111. Middle East Cardiac Biomarkers Testing, by Location of Testing USD Million (2015-2020)
  • Table 112. Africa Cardiac Biomarkers Testing, by Type USD Million (2015-2020)
  • Table 113. Africa Cardiac Biomarkers Testing, by Application USD Million (2015-2020)
  • Table 114. Africa Cardiac Biomarkers Testing, by Product USD Million (2015-2020)
  • Table 115. Africa Cardiac Biomarkers Testing, by Location of Testing USD Million (2015-2020)
  • Table 116. North America Cardiac Biomarkers Testing, by Country USD Million (2015-2020)
  • Table 117. North America Cardiac Biomarkers Testing, by Type USD Million (2015-2020)
  • Table 118. North America Cardiac Biomarkers Testing, by Application USD Million (2015-2020)
  • Table 119. North America Cardiac Biomarkers Testing, by Product USD Million (2015-2020)
  • Table 120. North America Cardiac Biomarkers Testing, by Location of Testing USD Million (2015-2020)
  • Table 121. United States Cardiac Biomarkers Testing, by Type USD Million (2015-2020)
  • Table 122. United States Cardiac Biomarkers Testing, by Application USD Million (2015-2020)
  • Table 123. United States Cardiac Biomarkers Testing, by Product USD Million (2015-2020)
  • Table 124. United States Cardiac Biomarkers Testing, by Location of Testing USD Million (2015-2020)
  • Table 125. Canada Cardiac Biomarkers Testing, by Type USD Million (2015-2020)
  • Table 126. Canada Cardiac Biomarkers Testing, by Application USD Million (2015-2020)
  • Table 127. Canada Cardiac Biomarkers Testing, by Product USD Million (2015-2020)
  • Table 128. Canada Cardiac Biomarkers Testing, by Location of Testing USD Million (2015-2020)
  • Table 129. Mexico Cardiac Biomarkers Testing, by Type USD Million (2015-2020)
  • Table 130. Mexico Cardiac Biomarkers Testing, by Application USD Million (2015-2020)
  • Table 131. Mexico Cardiac Biomarkers Testing, by Product USD Million (2015-2020)
  • Table 132. Mexico Cardiac Biomarkers Testing, by Location of Testing USD Million (2015-2020)
  • Table 133. Cardiac Biomarkers Testing: by Type(USD/Units)
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. Company Basic Information, Sales Area and Its Competitors
  • Table 141. Company Basic Information, Sales Area and Its Competitors
  • Table 142. Company Basic Information, Sales Area and Its Competitors
  • Table 143. Company Basic Information, Sales Area and Its Competitors
  • Table 144. Cardiac Biomarkers Testing: by Type(USD Million)
  • Table 145. Cardiac Biomarkers Testing Myocardial Muscle Creatine Kinase (CK-MB) , by Region USD Million (2021-2026)
  • Table 146. Cardiac Biomarkers Testing Troponins (T and I) , by Region USD Million (2021-2026)
  • Table 147. Cardiac Biomarkers Testing Myoglobin , by Region USD Million (2021-2026)
  • Table 148. Cardiac Biomarkers Testing Brain Natriuretic Peptide (BNPs) or NT-proBNP , by Region USD Million (2021-2026)
  • Table 149. Cardiac Biomarkers Testing Ischemia-modified Albumin (IMA) , by Region USD Million (2021-2026)
  • Table 150. Cardiac Biomarkers Testing Others , by Region USD Million (2021-2026)
  • Table 151. Cardiac Biomarkers Testing: by Application(USD Million)
  • Table 152. Cardiac Biomarkers Testing Myocardial Infarction , by Region USD Million (2021-2026)
  • Table 153. Cardiac Biomarkers Testing Congestive Heart Failure , by Region USD Million (2021-2026)
  • Table 154. Cardiac Biomarkers Testing Acute Coronary Syndrome , by Region USD Million (2021-2026)
  • Table 155. Cardiac Biomarkers Testing Atherosclerosis , by Region USD Million (2021-2026)
  • Table 156. Cardiac Biomarkers Testing Others , by Region USD Million (2021-2026)
  • Table 157. Cardiac Biomarkers Testing: by Product(USD Million)
  • Table 158. Cardiac Biomarkers Testing Instruments , by Region USD Million (2021-2026)
  • Table 159. Cardiac Biomarkers Testing Chemiluminescence , by Region USD Million (2021-2026)
  • Table 160. Cardiac Biomarkers Testing Immunofluorescence , by Region USD Million (2021-2026)
  • Table 161. Cardiac Biomarkers Testing ELISA , by Region USD Million (2021-2026)
  • Table 162. Cardiac Biomarkers Testing Immunochromatography , by Region USD Million (2021-2026)
  • Table 163. Cardiac Biomarkers Testing Reagents and Kits , by Region USD Million (2021-2026)
  • Table 164. Cardiac Biomarkers Testing: by Location of Testing(USD Million)
  • Table 165. Cardiac Biomarkers Testing Point of Care Testing , by Region USD Million (2021-2026)
  • Table 166. Cardiac Biomarkers Testing Laboratory Testing , by Region USD Million (2021-2026)
  • Table 167. South America Cardiac Biomarkers Testing, by Country USD Million (2021-2026)
  • Table 168. South America Cardiac Biomarkers Testing, by Type USD Million (2021-2026)
  • Table 169. South America Cardiac Biomarkers Testing, by Application USD Million (2021-2026)
  • Table 170. South America Cardiac Biomarkers Testing, by Product USD Million (2021-2026)
  • Table 171. South America Cardiac Biomarkers Testing, by Location of Testing USD Million (2021-2026)
  • Table 172. Brazil Cardiac Biomarkers Testing, by Type USD Million (2021-2026)
  • Table 173. Brazil Cardiac Biomarkers Testing, by Application USD Million (2021-2026)
  • Table 174. Brazil Cardiac Biomarkers Testing, by Product USD Million (2021-2026)
  • Table 175. Brazil Cardiac Biomarkers Testing, by Location of Testing USD Million (2021-2026)
  • Table 176. Argentina Cardiac Biomarkers Testing, by Type USD Million (2021-2026)
  • Table 177. Argentina Cardiac Biomarkers Testing, by Application USD Million (2021-2026)
  • Table 178. Argentina Cardiac Biomarkers Testing, by Product USD Million (2021-2026)
  • Table 179. Argentina Cardiac Biomarkers Testing, by Location of Testing USD Million (2021-2026)
  • Table 180. Rest of South America Cardiac Biomarkers Testing, by Type USD Million (2021-2026)
  • Table 181. Rest of South America Cardiac Biomarkers Testing, by Application USD Million (2021-2026)
  • Table 182. Rest of South America Cardiac Biomarkers Testing, by Product USD Million (2021-2026)
  • Table 183. Rest of South America Cardiac Biomarkers Testing, by Location of Testing USD Million (2021-2026)
  • Table 184. Asia Pacific Cardiac Biomarkers Testing, by Country USD Million (2021-2026)
  • Table 185. Asia Pacific Cardiac Biomarkers Testing, by Type USD Million (2021-2026)
  • Table 186. Asia Pacific Cardiac Biomarkers Testing, by Application USD Million (2021-2026)
  • Table 187. Asia Pacific Cardiac Biomarkers Testing, by Product USD Million (2021-2026)
  • Table 188. Asia Pacific Cardiac Biomarkers Testing, by Location of Testing USD Million (2021-2026)
  • Table 189. China Cardiac Biomarkers Testing, by Type USD Million (2021-2026)
  • Table 190. China Cardiac Biomarkers Testing, by Application USD Million (2021-2026)
  • Table 191. China Cardiac Biomarkers Testing, by Product USD Million (2021-2026)
  • Table 192. China Cardiac Biomarkers Testing, by Location of Testing USD Million (2021-2026)
  • Table 193. Japan Cardiac Biomarkers Testing, by Type USD Million (2021-2026)
  • Table 194. Japan Cardiac Biomarkers Testing, by Application USD Million (2021-2026)
  • Table 195. Japan Cardiac Biomarkers Testing, by Product USD Million (2021-2026)
  • Table 196. Japan Cardiac Biomarkers Testing, by Location of Testing USD Million (2021-2026)
  • Table 197. India Cardiac Biomarkers Testing, by Type USD Million (2021-2026)
  • Table 198. India Cardiac Biomarkers Testing, by Application USD Million (2021-2026)
  • Table 199. India Cardiac Biomarkers Testing, by Product USD Million (2021-2026)
  • Table 200. India Cardiac Biomarkers Testing, by Location of Testing USD Million (2021-2026)
  • Table 201. South Korea Cardiac Biomarkers Testing, by Type USD Million (2021-2026)
  • Table 202. South Korea Cardiac Biomarkers Testing, by Application USD Million (2021-2026)
  • Table 203. South Korea Cardiac Biomarkers Testing, by Product USD Million (2021-2026)
  • Table 204. South Korea Cardiac Biomarkers Testing, by Location of Testing USD Million (2021-2026)
  • Table 205. Taiwan Cardiac Biomarkers Testing, by Type USD Million (2021-2026)
  • Table 206. Taiwan Cardiac Biomarkers Testing, by Application USD Million (2021-2026)
  • Table 207. Taiwan Cardiac Biomarkers Testing, by Product USD Million (2021-2026)
  • Table 208. Taiwan Cardiac Biomarkers Testing, by Location of Testing USD Million (2021-2026)
  • Table 209. Australia Cardiac Biomarkers Testing, by Type USD Million (2021-2026)
  • Table 210. Australia Cardiac Biomarkers Testing, by Application USD Million (2021-2026)
  • Table 211. Australia Cardiac Biomarkers Testing, by Product USD Million (2021-2026)
  • Table 212. Australia Cardiac Biomarkers Testing, by Location of Testing USD Million (2021-2026)
  • Table 213. Rest of Asia-Pacific Cardiac Biomarkers Testing, by Type USD Million (2021-2026)
  • Table 214. Rest of Asia-Pacific Cardiac Biomarkers Testing, by Application USD Million (2021-2026)
  • Table 215. Rest of Asia-Pacific Cardiac Biomarkers Testing, by Product USD Million (2021-2026)
  • Table 216. Rest of Asia-Pacific Cardiac Biomarkers Testing, by Location of Testing USD Million (2021-2026)
  • Table 217. Europe Cardiac Biomarkers Testing, by Country USD Million (2021-2026)
  • Table 218. Europe Cardiac Biomarkers Testing, by Type USD Million (2021-2026)
  • Table 219. Europe Cardiac Biomarkers Testing, by Application USD Million (2021-2026)
  • Table 220. Europe Cardiac Biomarkers Testing, by Product USD Million (2021-2026)
  • Table 221. Europe Cardiac Biomarkers Testing, by Location of Testing USD Million (2021-2026)
  • Table 222. Germany Cardiac Biomarkers Testing, by Type USD Million (2021-2026)
  • Table 223. Germany Cardiac Biomarkers Testing, by Application USD Million (2021-2026)
  • Table 224. Germany Cardiac Biomarkers Testing, by Product USD Million (2021-2026)
  • Table 225. Germany Cardiac Biomarkers Testing, by Location of Testing USD Million (2021-2026)
  • Table 226. France Cardiac Biomarkers Testing, by Type USD Million (2021-2026)
  • Table 227. France Cardiac Biomarkers Testing, by Application USD Million (2021-2026)
  • Table 228. France Cardiac Biomarkers Testing, by Product USD Million (2021-2026)
  • Table 229. France Cardiac Biomarkers Testing, by Location of Testing USD Million (2021-2026)
  • Table 230. Italy Cardiac Biomarkers Testing, by Type USD Million (2021-2026)
  • Table 231. Italy Cardiac Biomarkers Testing, by Application USD Million (2021-2026)
  • Table 232. Italy Cardiac Biomarkers Testing, by Product USD Million (2021-2026)
  • Table 233. Italy Cardiac Biomarkers Testing, by Location of Testing USD Million (2021-2026)
  • Table 234. United Kingdom Cardiac Biomarkers Testing, by Type USD Million (2021-2026)
  • Table 235. United Kingdom Cardiac Biomarkers Testing, by Application USD Million (2021-2026)
  • Table 236. United Kingdom Cardiac Biomarkers Testing, by Product USD Million (2021-2026)
  • Table 237. United Kingdom Cardiac Biomarkers Testing, by Location of Testing USD Million (2021-2026)
  • Table 238. Netherlands Cardiac Biomarkers Testing, by Type USD Million (2021-2026)
  • Table 239. Netherlands Cardiac Biomarkers Testing, by Application USD Million (2021-2026)
  • Table 240. Netherlands Cardiac Biomarkers Testing, by Product USD Million (2021-2026)
  • Table 241. Netherlands Cardiac Biomarkers Testing, by Location of Testing USD Million (2021-2026)
  • Table 242. Rest of Europe Cardiac Biomarkers Testing, by Type USD Million (2021-2026)
  • Table 243. Rest of Europe Cardiac Biomarkers Testing, by Application USD Million (2021-2026)
  • Table 244. Rest of Europe Cardiac Biomarkers Testing, by Product USD Million (2021-2026)
  • Table 245. Rest of Europe Cardiac Biomarkers Testing, by Location of Testing USD Million (2021-2026)
  • Table 246. MEA Cardiac Biomarkers Testing, by Country USD Million (2021-2026)
  • Table 247. MEA Cardiac Biomarkers Testing, by Type USD Million (2021-2026)
  • Table 248. MEA Cardiac Biomarkers Testing, by Application USD Million (2021-2026)
  • Table 249. MEA Cardiac Biomarkers Testing, by Product USD Million (2021-2026)
  • Table 250. MEA Cardiac Biomarkers Testing, by Location of Testing USD Million (2021-2026)
  • Table 251. Middle East Cardiac Biomarkers Testing, by Type USD Million (2021-2026)
  • Table 252. Middle East Cardiac Biomarkers Testing, by Application USD Million (2021-2026)
  • Table 253. Middle East Cardiac Biomarkers Testing, by Product USD Million (2021-2026)
  • Table 254. Middle East Cardiac Biomarkers Testing, by Location of Testing USD Million (2021-2026)
  • Table 255. Africa Cardiac Biomarkers Testing, by Type USD Million (2021-2026)
  • Table 256. Africa Cardiac Biomarkers Testing, by Application USD Million (2021-2026)
  • Table 257. Africa Cardiac Biomarkers Testing, by Product USD Million (2021-2026)
  • Table 258. Africa Cardiac Biomarkers Testing, by Location of Testing USD Million (2021-2026)
  • Table 259. North America Cardiac Biomarkers Testing, by Country USD Million (2021-2026)
  • Table 260. North America Cardiac Biomarkers Testing, by Type USD Million (2021-2026)
  • Table 261. North America Cardiac Biomarkers Testing, by Application USD Million (2021-2026)
  • Table 262. North America Cardiac Biomarkers Testing, by Product USD Million (2021-2026)
  • Table 263. North America Cardiac Biomarkers Testing, by Location of Testing USD Million (2021-2026)
  • Table 264. United States Cardiac Biomarkers Testing, by Type USD Million (2021-2026)
  • Table 265. United States Cardiac Biomarkers Testing, by Application USD Million (2021-2026)
  • Table 266. United States Cardiac Biomarkers Testing, by Product USD Million (2021-2026)
  • Table 267. United States Cardiac Biomarkers Testing, by Location of Testing USD Million (2021-2026)
  • Table 268. Canada Cardiac Biomarkers Testing, by Type USD Million (2021-2026)
  • Table 269. Canada Cardiac Biomarkers Testing, by Application USD Million (2021-2026)
  • Table 270. Canada Cardiac Biomarkers Testing, by Product USD Million (2021-2026)
  • Table 271. Canada Cardiac Biomarkers Testing, by Location of Testing USD Million (2021-2026)
  • Table 272. Mexico Cardiac Biomarkers Testing, by Type USD Million (2021-2026)
  • Table 273. Mexico Cardiac Biomarkers Testing, by Application USD Million (2021-2026)
  • Table 274. Mexico Cardiac Biomarkers Testing, by Product USD Million (2021-2026)
  • Table 275. Mexico Cardiac Biomarkers Testing, by Location of Testing USD Million (2021-2026)
  • Table 276. Cardiac Biomarkers Testing: by Type(USD/Units)
  • Table 277. Research Programs/Design for This Report
  • Table 278. Key Data Information from Secondary Sources
  • Table 279. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Cardiac Biomarkers Testing: by Type USD Million (2015-2020)
  • Figure 5. Global Cardiac Biomarkers Testing: by Application USD Million (2015-2020)
  • Figure 6. Global Cardiac Biomarkers Testing: by Product USD Million (2015-2020)
  • Figure 7. Global Cardiac Biomarkers Testing: by Location of Testing USD Million (2015-2020)
  • Figure 8. South America Cardiac Biomarkers Testing Share (%), by Country
  • Figure 9. Asia Pacific Cardiac Biomarkers Testing Share (%), by Country
  • Figure 10. Europe Cardiac Biomarkers Testing Share (%), by Country
  • Figure 11. MEA Cardiac Biomarkers Testing Share (%), by Country
  • Figure 12. North America Cardiac Biomarkers Testing Share (%), by Country
  • Figure 13. Global Cardiac Biomarkers Testing: by Type USD/Units (2015-2020)
  • Figure 14. Global Cardiac Biomarkers Testing share by Players 2020 (%)
  • Figure 15. Global Cardiac Biomarkers Testing share by Players (Top 3) 2020(%)
  • Figure 16. Global Cardiac Biomarkers Testing share by Players (Top 5) 2020(%)
  • Figure 17. BCG Matrix for key Companies
  • Figure 18. Abbott Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 19. Abbott Laboratories (United States) Revenue: by Geography 2020
  • Figure 20. Becton, Dickinson and Company (United States) Revenue, Net Income and Gross profit
  • Figure 21. Becton, Dickinson and Company (United States) Revenue: by Geography 2020
  • Figure 22. BioMerieux SA (France) Revenue, Net Income and Gross profit
  • Figure 23. BioMerieux SA (France) Revenue: by Geography 2020
  • Figure 24. Bio-Rad Laboratories, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 25. Bio-Rad Laboratories, Inc. (United States) Revenue: by Geography 2020
  • Figure 26. Danaher Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 27. Danaher Corporation (United States) Revenue: by Geography 2020
  • Figure 28. Roche Holding AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 29. Roche Holding AG (Switzerland) Revenue: by Geography 2020
  • Figure 30. Siemens AG (Germany) Revenue, Net Income and Gross profit
  • Figure 31. Siemens AG (Germany) Revenue: by Geography 2020
  • Figure 32. Thermo Fisher Scientific, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 33. Thermo Fisher Scientific, Inc. (United States) Revenue: by Geography 2020
  • Figure 34. PerkinElmer Inc. (United kingdom) Revenue, Net Income and Gross profit
  • Figure 35. PerkinElmer Inc. (United kingdom) Revenue: by Geography 2020
  • Figure 36. Tosoh Corporation (Japan) Revenue, Net Income and Gross profit
  • Figure 37. Tosoh Corporation (Japan) Revenue: by Geography 2020
  • Figure 38. Global Cardiac Biomarkers Testing: by Type USD Million (2021-2026)
  • Figure 39. Global Cardiac Biomarkers Testing: by Application USD Million (2021-2026)
  • Figure 40. Global Cardiac Biomarkers Testing: by Product USD Million (2021-2026)
  • Figure 41. Global Cardiac Biomarkers Testing: by Location of Testing USD Million (2021-2026)
  • Figure 42. South America Cardiac Biomarkers Testing Share (%), by Country
  • Figure 43. Asia Pacific Cardiac Biomarkers Testing Share (%), by Country
  • Figure 44. Europe Cardiac Biomarkers Testing Share (%), by Country
  • Figure 45. MEA Cardiac Biomarkers Testing Share (%), by Country
  • Figure 46. North America Cardiac Biomarkers Testing Share (%), by Country
  • Figure 47. Global Cardiac Biomarkers Testing: by Type USD/Units (2021-2026)
Some of the key companies/manufacturers profiled in the report
  • Abbott Laboratories (United States)
  • Becton, Dickinson and Company (United States)
  • BioMerieux SA (France)
  • Bio-Rad Laboratories, Inc. (United States)
  • Danaher Corporation (United States)
  • Roche Holding AG (Switzerland)
  • Siemens AG (Germany)
  • Thermo Fisher Scientific, Inc. (United States)
  • PerkinElmer Inc. (United kingdom)
  • Tosoh Corporation (Japan)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation